Comparison of granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells and G-CSF--stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation

HLA-identical bone marrow or stem cell transplantation from a sibling is the preferred treatment for patients with chronic myelogenous leukemia, bone marrow failure syndromes, relapsed acute leukemia, and specific inborn errors of metabolism. Several groups have shown that granulocyte colony-stimula...

Full description

Saved in:

Bibliographic Details
Published in:	Biology of blood and marrow transplantation Vol. 6; no. 4; pp. 434 - 440
Main Authors:	Serody, Jonathan S., Sparks, Scotty D., Lin, Yuhua, Capel, Eileen J., Bigelow, Sharon H., Kirby, Suzanne L., Gabriel, Don A., Wiley, Joseph M., Brecher, Mark E., Schell, Michael J., Folds, James, Shea, Thomas C.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-01-2000
Subjects:	Adolescent Adult Blood Cells Bone Marrow Cells Child Graft Survival Granulocyte Colony-Stimulating Factor - administration & dosage Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Histocompatibility Testing Humans Middle Aged Neoplasms - therapy Survival Analysis Transplantation, Homologous
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	HLA-identical bone marrow or stem cell transplantation from a sibling is the preferred treatment for patients with chronic myelogenous leukemia, bone marrow failure syndromes, relapsed acute leukemia, and specific inborn errors of metabolism. Several groups have shown that granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells (PBPCs) obtained from HLA-matched siblings are effective in reconstitution of marrow function after marrow ablative conditioning therapy. To evaluate whether G-CSF treatment before bone marrow harvest leads to enhanced recovery of PBPC counts and recovery from limited graft-versus-host disease (GVHD), we assessed the outcome of a sequential cohort of patients treated identically and then given either G-CSF--mobilized PBPCs or G-CSF--stimulated bone marrow from HLA-identical siblings. We show that the time to neutrophil engraftment is identical in the 2 cohorts, whereas platelet engraftment is earlier with the use of PBPCs. The incidence of acute GVHD was decreased, and that of chronic GVHD significantly decreased, in the group receiving bone marrow. Overall survival was not different between the 2 groups. Thus, G-CSF--stimulated bone marrow offers a source of stem cells that allows for early neutrophil engraftment with a decreased risk of GVHD. Biol Blood Marrow Transplant 2000;6(4A):434-40.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	1083-8791 1523-6536
DOI:	10.1016/S1083-8791(00)70035-8